SAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Biogen Inc. (NASDAQ: BIIB) securities between February 3, 2022 and February 13, 2024, inclusive (the “Class Period”), have until Monday, July 22, 2024 to seek appointment as lead plaintiff in the Biogen class action lawsuit. Captioned Gray v. Biogen Inc., No. 24-cv-01444 (D. Colo.), the Biogen class action lawsuit charges Biogen and certain of Biogen’s top current and former executives wit ...

Jeito Capital consolidates its support in CatalYm with a renewed participation in a $150 million financing This new financing will support broad late-stage clinical development program for visugromab, CatalYm's lead product candidate in cancer immunotherapy.After a first investment as co-lead investor in CatalYm's €50 million series C financing (November 2022), Jeito's new participation in this oversubscribed round, alongside new international biopharma investors, confirms CatalYm's strong progress and pot ...

Jeito Capital consolidates its support in CatalYm with a renewed participation in a $150 million financing This new financing will support broad late-stage clinical development program for visugromab, CatalYm’s lead product candidate in cancer immunotherapy.After a first investment as co-lead investor in CatalYm’s €50 million series C financing (November 2022), Jeito’s new participation in this oversubscribed round, alongside new international biopharma investors, confirms CatalYm’s strong progress and pot ...

LOS ANGELES, July 16, 2024 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Biogen Inc. ("Biogen" or "the Company") (NASDAQ:BIIB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of BIIB during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff ...

文章核心观点 Bernstein Liebhard LLP提醒Biogen投资者证券集体诉讼推选首席原告期限仅剩7天，需在7月22日前提交文件，诉讼称Biogen夸大相关工作成效 [1][2] 诉讼相关 - 证券集体诉讼针对2022年2月3日至2024年2月13日购买Biogen证券的投资者 [1] - 若想担任首席原告需在2024年7月22日前提交文件，不担任也可参与赔偿分配，不行动则为缺席集体成员 [1] - 诉讼称Biogen夸大提升透明度、公司治理、合规控制程序的努力及成效 [2] 律所情况 - 代理按风险代理收费，股东无需支付费用 [2] - 自1993年以来为客户追回超35亿美元 [2] - 代表个人投资者，受大型公私养老基金委托监控资产和诉讼 [2] - 因成功诉讼数百起集体诉讼，13次登上《国家法律杂志》“原告热门名单”，连续16年入选《法律500强》 [2] 联系方式 - 可在Biogen Inc. Shareholder Class Action Lawsuit提交表格，或联系投资者关系经理Peter Allocco，邮箱pallocco@bernlieb.com，电话(212) 951 - 2030 [1][3] - 律所地址为纽约东40街10号，电话(212) 779 - 1414 [3]

文章核心观点 格罗斯律师事务所通知百健公司（Biogen Inc.）股东，鼓励在特定时间段购买该公司股票的股东联系律所，可能被任命为首席原告，指控百健公司在特定时期发布虚假或误导性声明，股东可在规定时间内登记参与集体诉讼 [1][2][3] 分组1：集体诉讼相关信息 - 鼓励在2022年2月3日至2024年2月13日期间购买百健公司股票的股东联系律所，可能被任命为首席原告，参与集体诉讼无需成为首席原告 [1][2] - 集体诉讼登记截止日期为2024年7月22日，股东可通过指定链接登记信息 [3] - 登记后将被纳入投资组合监控软件，以获取案件进展更新，参与案件无成本或义务 [3] 分组2：指控内容 - 百健公司夸大了提升透明度、公司治理和合规控制程序的努力及效果 [2] - 公司在海外业务运营中合规控制程序不足 [2] - 公司及其员工在多个国家存在非法或不当行为 [2] - 上述情况使公司面临政府和监管审查及执法行动的更高风险，以及重大法律、财务和声誉损害 [2] - 百健公司夸大了其阿尔茨海默病相关产品组合的实力，包括与卫材公司在推出和推广Leqembi方面的合作成果 [2] - 公司淡化了收购Reata对2023财年非公认会计准则摊薄每股收益的负面影响 [2] - 上述所有情况可能对百健公司2023年业绩产生重大负面影响，公司公开声明在所有相关时间均存在重大虚假和误导性 [2] 分组3：律所信息 - 格罗斯律师事务所是全国知名的集体诉讼律师事务所，致力于保护因欺诈和非法商业行为受损的投资者权益，确保公司遵守负责任的商业行为和良好的企业公民标准 [4] - 律所联系方式：地址为纽约市西38街15号12楼，邮箱为dg@securitiesclasslaw.com，电话为(646) 453 - 8903 [4]

SAN DIEGO, July 13, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Biogen Inc. (NASDAQ: BIIB) securities between February 3, 2022 and February 13, 2024, all dates inclusive (the “Class Period”), have until July 22, 2024 to seek appointment as lead plaintiff in the Biogen class action lawsuit. Captioned Gray v. Biogen Inc., No. 24-cv-01444 (D. Colo.), the Biogen class action lawsuit charges Biogen as well as certain of Biogen’s top current and former execu ...

NEW YORK, July 12, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Biogen Inc. (NASDAQ: BIIB).Shareholders who purchased shares of BIIB during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/biogen-loss-submission-form/?id=90352&from=4 CLASS PERIOD: February 3, 2022 to February 13, 2 ...

NEW YORK, July 10, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Biogen investors who were adversely affected by alleged securities fraud between February 3, 2022 and February 13, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/biogen-lawsuit-submission-form? ...

NEW YORK, July 09, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Biogen Inc. (NASDAQ: BIIB). Shareholders who purchased shares of BIIB during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/biogen-loss-submission-form/?id=89664&from=3 CLASS PERIOD: February 3, 2022 to Februar ...